Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui Sells 49,271 Shares

Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui sold 49,271 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $5.01, for a total value of $246,847.71. Following the completion of the transaction, the chief executive officer now owns 2,003,147 shares of the company’s stock, valued at $10,035,766.47. The trade was a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Claude Maraoui also recently made the following trade(s):

• On Friday, March 7th, Claude Maraoui sold 14,905 shares of Journey Medical stock. The stock was sold at an average price of $5.01, for a total value of $74,674.05.
• On Wednesday, March 5th, Claude Maraoui sold 18,147 shares of Journey Medical stock. The stock was sold at an average price of $5.13, for a total transaction of $93,094.11.
• On Monday, March 3rd, Claude Maraoui sold 23,508 shares of Journey Medical stock. The shares were sold at an average price of $5.19, for a total transaction of $122,006.52.

Journey Medical Trading Up 3.0 %

NASDAQ:DERM traded up $0.15 during trading hours on Tuesday, reaching $5.15. The company’s stock had a trading volume of 78,538 shares, compared to its average volume of 94,051. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. The firm has a market capitalization of $107.58 million, a price-to-earnings ratio of -5.48 and a beta of 0.97. The firm has a 50-day simple moving average of $4.62 and a 200-day simple moving average of $5.09. Journey Medical Co. has a 1 year low of $2.85 and a 1 year high of $6.89.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of DERM. Geode Capital Management LLC grew its position in Journey Medical by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock worth $613,000 after acquiring an additional 12,882 shares during the last quarter. Nwam LLC bought a new stake in Journey Medical in the third quarter valued at approximately $59,000. PVG Asset Management Corp boosted its stake in shares of Journey Medical by 5.7% during the third quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock valued at $947,000 after purchasing an additional 9,005 shares during the period. Kovitz Investment Group Partners LLC bought a new position in shares of Journey Medical in the third quarter worth approximately $66,000. Finally, Citadel Advisors LLC purchased a new position in shares of Journey Medical in the fourth quarter worth $174,000. Hedge funds and other institutional investors own 7.25% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.